14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $31.23 $31.23 Wednesday, 1st May 2024 IMGN stock ended at $31.23. During the day the stock fluctuated 0% from a day low at $31.23 to a day high of $31.23.
90 days $29.21 $31.25
52 weeks $10.31 $31.25

Historical ImmunoGen prices

Date Open High Low Close Volume
Feb 20, 2024 $31.23 $31.23 $31.23 $31.23 0
Feb 16, 2024 $31.23 $31.23 $31.23 $31.23 0
Feb 15, 2024 $31.23 $31.23 $31.23 $31.23 0
Feb 14, 2024 $31.23 $31.23 $31.23 $31.23 0
Feb 13, 2024 $31.23 $31.23 $31.23 $31.23 0
Feb 12, 2024 $31.23 $31.23 $31.23 $31.23 0
Feb 09, 2024 $31.24 $31.25 $31.22 $31.23 44 213 377
Feb 08, 2024 $31.23 $31.24 $31.22 $31.23 49 292 629
Feb 07, 2024 $29.50 $29.69 $29.41 $29.55 10 382 452
Feb 06, 2024 $29.31 $29.55 $29.25 $29.51 8 601 358
Feb 05, 2024 $29.26 $29.39 $29.24 $29.30 4 563 189
Feb 02, 2024 $29.36 $29.47 $29.21 $29.26 6 286 402
Feb 01, 2024 $29.35 $29.48 $29.26 $29.36 3 078 012
Jan 31, 2024 $29.53 $29.60 $29.15 $29.32 5 860 097
Jan 30, 2024 $29.48 $29.54 $29.37 $29.39 3 899 300
Jan 29, 2024 $29.57 $29.62 $29.36 $29.42 3 837 082
Jan 26, 2024 $29.53 $29.57 $29.49 $29.57 2 676 222
Jan 25, 2024 $29.56 $29.58 $29.49 $29.50 4 402 488
Jan 24, 2024 $29.50 $29.54 $29.42 $29.50 2 976 055
Jan 23, 2024 $29.59 $29.59 $29.44 $29.44 6 065 400
Jan 22, 2024 $29.53 $29.62 $29.52 $29.54 5 108 976
Jan 19, 2024 $29.58 $29.61 $29.51 $29.52 3 362 804
Jan 18, 2024 $29.63 $29.63 $29.51 $29.53 3 970 637
Jan 17, 2024 $29.62 $29.70 $29.58 $29.59 2 430 994
Jan 16, 2024 $29.72 $29.72 $29.58 $29.63 3 876 528
Click to get the best stock tips daily for free!

About ImmunoGen

ImmunoGen ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and... IMGN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT